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The impact of recent developments in technologies which enable 
the increased use of biocatalysts  
Aoife M. Foley,[a] and Anita R. Maguire*[b] 
 
Abstract: While biocatalytic transformations are very powerful in 
enantioselective synthesis, frequently occurring under mild conditions 
and with extraordinary selectivity, there are practical challenges 
associated with the use of biocatalysis such as limited substrate 
scope, stability and reusability. Recent technological developments, 
for example immobilization, continuous flow and molecular biology, all 
contribute towards enhancing the use of enzymes in synthesis. 
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Biocatalysis is a useful tool in chemical synthesis in particular in 
relation to enantioselective synthesis, and recent advances in 
technology provide the resources to expand use of biocatalysis 
beyond the natural substrates, as well as to enhance the stability 
of enzymes and scope of enzymatic transformations.[1]  
1. Enabling technology 
Rapid improvements in underpinning technology ranging from 
developments in molecular biology, which enables engineering of 
cells for the coexpression of multiple enzymes, thereby enabling 
cascade processes, discovery and design of novel biocatalysts, 
immobilization and use of continuous processing have 
significantly enhanced the synthetic utility of biocatalysis as 
discussed in the individual sections below.  
1.1 Engineering cells for coexpression of multiple enzymes 
& cascade biocatalysis 
Because of the extraordinary selectivity of biocatalysts, they can 
be particularly suited to use in cascade systems, where the 
product from one reaction is further reacted without the need for 
isolation. Biocatalysts can be used both with other biocatalysts or 
with chemocatalysts.[2] The topic of multi-enzymatic cascades has 
been reviewed recently.[3] E. coli and other host organisms can be 
used to coexpress multiple enzymes in a cascade bioreactor. All 
of the enzymes can be produced by the same cell by modification 
of the plasmid(s) which are inserted into the expression vector. 
The use of multiple enzymes in a one-pot reaction can be 
attractive, because of the specificity of enzymes, minimizing 
cross-reaction. 
The combination of coexpressed enoate reductase (ERED) and 
amine transaminase (ATA) has been recently reported (Scheme 
1).[4] The stereochemistry at the β-position is determined by the 
enoate reductase, using either an (S)- or (R)- selective enoate 
reductase and the use of the appropriate transaminase gives 
either (S)- or (R)- stereochemistry at the amine. All four 
diastereomers of amine 1 can be accessed by use of the 
appropriate combination of biocatalysts. Initially the 
diastereoselectivity of the transaminases was poor (14% de), but 
the proteins were modified using directed evolution. Two small 
changes gave improved diastereoselectivity (up to 97% de). 
Following this, the enoate reductase was modified to give better 
enantioselectivity in the reduction of 2.[5] The stereochemistry at 
the beta-position is determined by the ene-reductase, and the 
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amine stereochemistry is controlled by the transaminase. 
Although this is a good example of coexpression and engineering 
of enzymes, lactate dehydrogenase and glucose dehydrogenase 
required for cofactor regeneration still had to be added separately. 
 
Scheme 1. Coexpression of multiple enzymes for the synthesis of cyclic 
amines 
Turner et al. used a three enzyme one-pot cascade for the 
synthesis of substituted piperidines and pyrrolidines (Scheme 2). 
Reduction of the carboxylic acid by carboxylic acid reductase 
(CAR), gave an aldehyde substrate for the transaminases (ω-TA); 
the resulting imine was then reduced by an imine reductase 
(IRED). By changing the position of the substituent on the 
substrate, isomeric products were obtained.[6] Further work by the 
same group carried out the same reactions, but in this case 
coexpressing the required biocatalysts in the same cell 
expression system.[7]  
 
Scheme 2. Synthesis of disubstituted pyrrolidines and piperidines 
A one-pot epoxidation-isomerization-oxidation to make terminal 
acids from terminal alkenes was recently reported (Scheme 3).[8] 
Workers from the same group, not satisfied with a three enzyme 
cascade, coexpressed up to nine enzymes in one host.[9] The 
eight-step nine enzyme reaction produced ᴅ-phenylglycine 3 from 
L-phenylalanine 4 in a cyanide-free synthesis (Scheme 4), using 
only ammonia, glucose and atmospheric oxygen. Phenylalanine 
ammonia lyase (PAL) and phenylacrylic acid decarboxylase 
(PAD) catalyze the loss of ammonia and carbon dioxide, 
respectively to produce styrene 5. Epoxidation using a styrene 
monooxygenase (SMO) and hydrolysis using an epoxide 
hydrolase (SpEH) gives intermediate diol 6. The diol 6 undergoes 
two oxidation steps, catalyzed by an alcohol dehydrogenase and 
an aldehyde dehydrogenase (AlkJ and EcALDH, respectively) to 
furnish (S)-mandelic acid (S)-7, which is further oxidized to the α-
keto acid 8 by (S)-mandelate dehydrogenase (SMDH). Ammonia 
transfer is the final step in the eight-step cascade, catalyzed by ᴅ-
phenylglycine ammonia transferase (DpgAT); glutamate 
dehydrogenase (GluDH) is used to regenerate the amine donor 
using ammonia. The specificity of each of these enzymes means 
that the product of one reaction is used by another enzyme, with 
the enzymes selected to avoid cross reaction.  
 
Scheme 3. Whole cell cascades: from alkenes to carboxylic acids 
 
Scheme 4. Whole cells coexpressing nine enzymes, the synthesis of ᴅ-phenyl 
glycine 3 
A series of β-hydroxy ketones and the acylated β-hydroxy ketones 
were synthesized by combination of two lipases (Scheme 5).[10] 
The first step is the decarboxylative aldol reaction in the presence 
of immobilized Mucor miehei lipase, followed by the kinetic 
resolution of the resulting β-hydroxy ketones. The catalysts were 
recycled up to three times, and some of the reactions were carried 
out at a >1 g scale.  
 
Scheme 5. Use of multiple lipases  
Use of two immobilized enzymes, which are coexpressed by E. 
coli, in the synthesis of diastereomers of fragrance molecules has 
been described. Two reductions are carried out, initial reduction 
of the alkene, followed by reduction of the ketone (Scheme 6).[11] 
One of the main advantages of this is it is an economical route to 
the fragrance molecules 9; another is that the unstable ketone 10 
is not isolated. In fact, the reduction of the ketone proceeds with 
higher diastereoselectivity when combined with the ene-
reductase in a one-pot reaction than when the reactions are 
carried out sequentially. This is because the compound with the 
labile α-stereocentre is not isolated when the two enzymes are 
used together. Workers from the same group also combined four 






different enzymes, this time in addition to the ADH and ene-
reductase, GDH and a lipase were used in the synthesis of 
bromodiol 11, a precursor to the tetrahydrofuran 12, which is also 
a fragrance molecule (Scheme 7).[12] The substrate was modified, 
so that after reaction with the ene-reductase and alcohol 
dehydrogenase, it would give a suitable substrate for the lipase, 
as well as furnishing enantiopure products from the bioreductions. 
Again, the one-pot strategy works better than sequential addition 
of the biocatalysts.  
 
Scheme 6. Combination of an ene-reductase (ERED) with either (R)- or (S)-
selective alcohol dehydrogenase (ADH) 
 
Scheme 7. Four enzyme cascade for the synthesis of 11, an intermediate in 
the synthesis of odorant 12 
The coupling of reduction and oxidation reactions can be useful 
for a dynamic system, Turner et al. reported the use of a chemical 
reductant in conjunction with an oxidative biocatalyst (Scheme 
8).[13] In this system, the initial step is mediated by either an (S)- 
or (R)-selective amine transaminase (ATA), and the resulting 
amine 13 can cyclize to give imine 14. The imine 14 is non-
selectively reduced to 15. Only one diastereomer is oxidized back 
to 14, eventually only one product is isolated, as the monoamine 
oxidase-favored diastereomer is continually oxidized, allowing the 
buildup of only one product. Gotor-Fernández et al. reported a 
related transamination, using γ- and δ- ketoesters. The ketone is 
reduced by a transaminase (Scheme 9) and the cyclization of the 
resulting amino esters result in γ- and δ- lactams.[14] The use of 
amino alcohols has been recently reported in the synthesis of β-, 
γ- or δ-lactams, in a bienzymatic cascade.[15]  
The use of engineered cells to coexpress enzymes can allow 
more efficient reactions by eliminating the need of intermediate 
purification of potentially labile compounds. The use of enzymes 
in a one-pot reaction can be overall more efficient, as it can 
reduce the isolation required, which can potentially reduce the 
time needed for the overall process. 
 
Scheme 8. Using a chemical reductant in combination with a biocatalyst 
  
Scheme 9. Biocatalytic reduction, followed by spontaneous cyclization 
1.2. Biotechnology: metagenomics, directed evolution and 
rational design 
The modification of reaction conditions to optimize the 
performance of enzymes is widely used, but the use of molecular 
biology techniques, such as directed evolution, rational design 
and genome mining can increase the potential library of 
biocatalysts enormously.[16] The larger the library of genetic 
material there is to work from, the better the chance of finding an 
enzyme which will carry out novel reactions or which has 
synthetically diverse substrate specificity.[17] The amount of 
organisms which can be cultured under laboratory conditions is 
limited to approximately 1–2% of all organisms, meaning that 
traditional methods for accessing genetic diversity are limited to 
those organisms which can be cultured.[18] Genetic sequencing 
and metagenomic techniques can be used to identify genes which 
encode for proteins, which otherwise would be inaccessible to 
researchers via a culture dependent method.[19] The study of 
genetic material from unusual environments, such as high salt, 
high temperature, or low or high pH environments can give rise to 
biocatalysts which are suited to these environments i.e. high salt 
concentration, extreme temperatures and pH values. 
Metagenomics allows evaluation of sequences which have 
evolved over millions of years. There are two types of analysis 
associated with metagenomic data: functional screening or 
sequence-driven analysis. Functional screening involves the 
cloning of the metagenomic DNA into a host organism followed 
by searching for the desired biocatalytic activity.[20] Several factors 
can affect the success of this method, the major one being that 
the host cell may not, in fact, express the proteins of interest; 
additionally a high throughput screen is usually required and a 
suitable detection method is not always available.[21] Sequence-
driven analysis uses a characteristic conserved sequence as a 
“hook” or “probe” for picking out DNA which may code for a protein 
of interest. The catalytic triad is an example of a conserved motif 
which can be used in the identification of novel hydrolases.[22] 
The identification of novel enzymes alone may not suffice in the 
context of finding an enzyme with desired activity/selectivity; for 
this, genetic mutation, either random or by design, can offer 
greater opportunities to tailor the enzymes for the required 






functionality.[23] Directed evolution is a technique which has been 
successfully applied to the expression of modified biocatalysts.[24] 
By examination of the structure of the biocatalyst through 
molecular docking techniques, as well as by comparison to 
biocatalysts of known function and structure, homology modelling 
can be used to identify mutations to improve activity of the 
biocatalyst.[25] Random mutations can also be used to give 
information on the effect of changing various residues in the active 
site.[26] 
An excellent example of directed evolution is the mutation of a 
transaminase for the asymmetric reduction step in the synthesis 
of Sitagliptin 16. Sitagliptin 16 (marketed as Januvia) is an 
antidiabetic drug developed and marketed by Merck & Co. In 
conjunction with Codexis, a biocatalyst was identified for the 
reductive amination of the intermediate 17.[27] Through the use of 
directed evolution, the poorly performing wild-type enzyme was 
extensively mutated until a biocatalyst with the desired activity 
was identified. In addition to this, the solvent tolerability and 
substrate scope were expanded beyond what is normally found in 
wild type transaminases, especially in the ability of the enzyme to 
accept a substrate with two bulky groups adjacent to the reaction 
site. Following this, Bornscheuer et al. reported the resolution of 
bulky substrates 18 and 19 (Figure 1) through rational design of a 
wild-type enzyme, requiring only four mutations.[28] 
 
Scheme 10. Synthesis of sitagliptin 16 
 
Figure 1. Bulky substrates 
The use of mutated enzymes for non-natural substrates is a 
growing area of interest, and has recently been reviewed.[16a;29] It 
is potentially a very useful enabling strategy, and as the 
techniques available for enzyme modification and evolution are 
continuously improving, the possibilities are growing.[16a;29] The 
pioneering work of Arnold et al. showed the potential for the use 
of directed evolution.[30] Recently Arnold’s group has reported the 
use of mutated P450 enzymes for olefin transformations, 
including cyclopropanation via carbene transfer, to furnish 
cyclopropane 20, an intermediate in the synthesis of ticagrelor 21 
(Scheme 11).[31] As well as this, workers from the same group 
have reported the functionalization of benzylic C–H bonds by a 
engineered iron-heme enzyme (Scheme 12).[32] Diazo and azide 
containing compounds are not traditionally accepted by enzymes; 
the use of directed evolution has allowed enzymes to be 
developed which make use of these useful intermediates. 
 
Scheme 11. Cyclopropanation catalyzed by engineered heme protein 
 
Scheme 12. Enzymatic C–H amination 
The use of directed evolution and metagenomic analysis is a 
powerful combination for the modification and improvement of 
existing biocatalysts as well as for the discovery of new 
biocatalysts.  
1.3. Immobilization 
Immobilization of biocatalysts offers a number of distinct 
advantages from a synthetic perspective: enhanced stability of 
enzymes, greatly enhanced ease of use and potential to recycle, 
and accessibility to the non-expert, especially through the use of 
commercially available immobilized enzymes, as described in a 
series of recent reviews.[33] Immobilization of biocatalysts, free 
enzymes or whole cells, can protect the enzymes from product 
inhibition, variations in temperature or pH; it also adds economic 
value to the biocatalysts by allowing recovery and reuse.[34] 
Recent developments in the support media available (including 
biodegradable chitin and chitosan, magnetic supports, silica) 
provides greater choice for the immobilization of biocatalysts 
depending on the requirements of an individual process.[35] 
There are three types of immobilization: binding to a support, 
entrapment (also called encapsulation), and cross linking (Figure 
2, A, B and C, respectively).[36]  
 
Figure 2. Modes of immobilization of biocatalysts  
Lipases are commonly immobilized on hydrophobic supports; this 
can increase their activity by holding them in the open or active 
conformation.[37] Specific interactions, for example the use of 
fusion enzymes, allows better control over the activity of the 






enzyme, as the part of the protein interacting with the support is 
essentially separate from the protein. Fusion proteins involve the 
addition of a sequence for a binding peptide to the enzyme to 
allow specific immobilization, and is highly useful.[38] The 
immobilization of affinity labelled (e.g. his-tagged) enzymes 
directly from the whole cell preparation is even more 
advantageous than the immobilization of purified proteins as it 
combines the immobilization step with the purification step.[39] The 
concept of a one-step purification immobilization is potentially 
very useful and has been reviewed previously.[39a] For some 
varieties of tags and immobilizing supports, similar results for 
enzyme activity can be attained when immobilizing the pure 
protein and when using the crude cell extract, thus eliminating the 
need for pre-purification of the enzyme (Figure 3).[40] The 
availability of specialized immobilization carriers designed for 
enzymes is growing.[41]  
 
Figure 3. Simultaneous purification and immobilization of fusion proteins 
The use of magnetic supports coated with ligands or peptides for 
interaction with the tagged proteins allows facile separation of the 
supported catalyst for reuse. Recently, lipases from 
Thermomyces lanuginosus and Rhizopus oryzae have been 
immobilized on magnetic nanoparticles with retention of activity 
and increase in stability relative to the free enzyme; this also 
allowed the facile separation and recovery of the enzyme.[42] 
Lipases have also previously been immobilized on magnetic 
lauric acid-stabilized particles for the resolution of menthol.[43] 
Horseradish peroxidase has been immobilized on iron oxide 
nanospheres on chemically reduced graphene oxide which has 
been shown to be an effective immobilization medium.[44] Marszałł 
et al. immobilized lipases onto magnetic chitosan nanoparticles, 
improving both the resolution of (RS)-atenolol 22 and the 
recoverability and reusability of the lipase.[45] The advantage of 
these systems is that the immobilized biocatalysts can be readily 
recovered by magnetic separation, removing the need for a 
filtration step. Lipases immobilized on magnetic nanoparticles 
have also been used in microtube reactors.[46]  
Zhu et al. reported the use of a pH sensitive support for Candida 
rugosa lipase used in the hydrolysis of ketoprofen ester.[47] In this 
case, once the reaction was completed, a simple adjustment of 
the pH precipitated the support and allowed facile recovery 
(Figure 4). The immobilized enzyme survived several precipitation 
and dissolution cycles while retaining activity (46% activity after 8 
cycles) and increased the enantioselectivity relative to the free 
enzyme by 1.5-8.7 times.  
 
Figure 4. pH-Controlled solubility of enzyme support 
Wever et al. reported a method for covalent immobilization of an 
acid phosphatase, which retained the activity and the majority of 
the efficiency of the enzyme.[48] The immobilized enzyme was 
shown to be stable after a year of storage in buffer. The catalyst 
was also used in a continuous flow system to produce a range of 
phosphorylated alcohols at a gram scale, using a cheap 
phosphate donor. The methodology could allow the facile 
integration of the reaction in a large, multi-enzyme, continuous 
system.  
The use of epoxy-functionalized resins is advantageous because 
of their ease of use. They have been used to immobilize 
halohydrin dehydrogenases directly from the cell lysate, without 
need for prior purification.[49] Epoxy functionalized silica has been 
used as an efficient support for lipases in the resolution of 
ibuprofen esters.[50]  
The wide range of support materials available offers a number of 
approaches for the immobilization of enzymes leading to 
enhanced stability, as well as imparting desirable properties for 
facile recovery of the biocatalyst and product purification. 
1.4. Flow Chemistry in Combination with Biocatalysis 
Flow chemistry or continuous processing is an important and 
rapidly growing area of research and is an increasing area of 
focus in the synthesis of pharmaceutical compounds and fine 
chemicals.[51] In addition to the synthetic advantages outlined 
above, the immobilization of biocatalysts enables their use in 
continuous processing. From the point of view of biocatalysis, an 
important advantage of continuous processing relative to batch 
processing is that the enzymes can be somewhat protected from 
product inhibition, by continually removing the inhibitors of the 
enzymes as they are formed, the productivity of these biocatalysts 
can be increased. While one of the most significant synthetic 
problems addressed by flow processing is the use of hazardous 
intermediates,[52] other problems which can be addressed by 
continuous flow technology are those associated with scale-up of 
processes, such as heat and mass transfer and sufficient mixing 
of reagents, which can limit the utility of some reactions. The 
productivity of oxidases can be limited by the rate of oxygen 
uptake, a problem which has been addressed by flow 
technology.[53] Biocatalysts used in combination with continuous 
flow technology has been recently reviewed by a number of 
groups.[54] Microreactors allow precise control of mixing and 
temperature, and their use, in conjunction with biocatalysts has 
been described.[55]  






Recently, the enzymatic synthesis of nucleoside analogues using 
immobilized Lipozyme® catalyzed transesterification has been 
reported.[56] The regioselective reaction was carried out using a 
microflow reactor (Scheme 13). The use of microflow technology 
allowed the reduction in the amount of DMSO required to 
solubilize the uridine derivatives, as well as mild temperature and 
short reaction time. The use of this technology enabled large 
libraries of compounds to be generated quickly without the use of 
protecting groups. 
 
Scheme 13. Synthesis of nucleoside analogues using immobilized Lipozyme® 
Using various carboxylic acids, esters of geraniol 23 were 
synthesized by lipase-catalyzed transesterification in a flow 
system, using commercially available immobilized lipases in a 
packed bed reactor (Scheme 14).[57] The process optimization 
was carried out in flow; a batch reaction mimicking the optimized 
conditions for the reaction was carried out to compare the 
efficiencies in both systems. The continuous synthesis of geranyl 
propionate 24 has been carried out.[58] The lipase for the 
transformation was identified through the use of batch reactions 
and a range of supports were screened to maximize the 
immobilization efficiency in order to facilitate the transfer of the 
reaction to a continuous system. As well as this, the support 
system chosen increased the activity of the lipase by almost 30%. 
 
Scheme 14. Continuous synthesis of geranyl propionate 24 
Flow chemistry has been used to overcome the slow release of 
products in the synthesis of sesquiterpene 25 from 
farnesyldiphosphate using a terpene synthase as biocatalyst 
(Scheme 15).[59] Continuous extraction of the product from the 
aqueous layer is necessary to make the biocatalytic process 
viable. When compared to batch, the flow system offered many 
advantages. Under batch conditions high-speed mixing would be 
necessary to achieve continuous extraction of the terpene 
products from the aqueous layer; this can lead to denaturation of 
the enzyme by shearing. The flow system offered more control 
over the interactions of the biocatalyst with the solvent; correct 
solvent choice was crucial, as emulsion formation would impede 
phase separation and complicate product recovery. 
 
Scheme 15. Synthesis of (+)-25 
The combination of flow chemistry and biocatalysis has also been 
applied to the production of fats for the food industry, as an 
alternative to hydrogenation and chemical (trans)esterification.[60] 
An immobilized preparation of lipase from Thermomyces 
lanuginosus was used to convert soybean oil into semi-solid fats 
such as margarine and shortening, which are higher value 
products than the liquid oil starting materials. Biodiesel and other 
materials derived from vegetable oils or biobased oils are 
economically important, as they can be used as an alternative to 
petroleum based products.[61] Lipases can be used in the 
synthesis of biofuels from oil through (trans)esterification.[62] 
Immobilized CAL-B has been used in a continuous flow system 
for the synthesis of ceramides, important compounds in both the 
pharmaceutical and cosmetic industries.[63] Commercially 
available immobilized biocatalysts were evaluated for the 
synthesis of ketal protected fatty acid esters of fructose (Scheme 
16).[64] The best conditions for the reaction were identified in batch 
reactors, and used as a starting point for the development of 
continuous flow conditions. 
 
Scheme 16. Synthesis of ketal protected fatty acids 
Another example of a biocatalytic process which is improved by 
transfer to continuous flow is the synthesis of ursodeoxycholic 
acid 26 (Scheme 17).[65] The process in batch involved the use of 
four enzymes in a two-step one-pot system. After the first step in 
batch, the enzymes had to be inactivated by heat treatment to 
avoid a reverse reaction occurring. Not only was this step 
potentially costly and time-consuming but it also meant that the 
enzymes could not be reused. The system was transferred to flow 
to spatially separate the enzymes required for the first and second 
steps. The two enzymes for each step were co-immobilized. This 
resulted in a continuous process which avoided the need for heat 
treatment to denature the enzymes by spatially separating the 
enzymes for each step, and allowed reuse of the enzymes.  
Recently, Turner et al. have shown the use of flow chemistry for 
the lipase-catalyzed resolution of the cyclopropyl subunit 20 for 
the synthesis of ticagrelor 21 (Scheme 18).[66] The biphasic 
mixture of product and starting material was separated, and the 
organic material recirculated to increase the conversion. The 
asymmetric reduction of the chloroethyl precursor 27 was also 
reported, in this case using a ketoreductase from a metagenomic 






library.[67] The process for the synthesis of alcohol 28 was 
optimized to give up to 500 g/L substrate concentration. 
 
 
Scheme 17. Coimmobilization and combination of multiple enzymatic steps 
 
Scheme 18. Synthesis of ticagrelor 21 
Enzymatic desymmetrization of the prochiral diol 29 in continuous 
flow has recently been reported, as the first step in an entirely 
flow-based synthetic route to captopril 30 (Scheme 19).[68] In this 
system, not only was the entire synthesis carried out using flow 
chemistry, but the chemoenzymatic step is carried out using 
immobilized whole cells, instead of purified protein, which 
decreases the overall cost of the product, as the expense 
associated with purification of proteins is eliminated. 
 
Scheme 19. Synthesis of captopril 30 
Purified transaminase from Halomonas elongata containing a 
poly His-tag was immobilized on a metal-derivatized epoxy resin 
and the substrate scope explored through the use of flow 
chemistry.[69] Although this process required purification of the 
enzyme, the use of the immobilized enzyme had the advantage 
of being able to withstand higher flow rates than the previously 
reported immobilization of a similar whole cell system (0.78 vs. 
0.02 mL min−1).[70] The ability to use a higher flow rate is important 
as it allows higher productivity. When the same immobilization 
procedure was applied to the crude cell extract, the transaminase 
was also successfully immobilized, eliminating the need for a 
separate enzyme purification step. In addition to this, a “catch-
and-release” in-line product purification was added. By trapping 
the amine products on either a column of silica gel or an acidic 
resin the amine product was separated from unreacted starting 
material (Scheme 20).[69-70] 
 
Scheme 20. Using continuous processing and in-line purification 
In a complementary approach, covalent immobilization of 
HaloTag® modified proteins directly from the whole cell has been 
reported.[71] Here tagged fusion enzymes are immobilized directly 
from the crude cell extract onto a resin pre-packed into a flow 
reactor, eliminating a costly separate purification step by 
combination with the immobilization step (Figure 3). Using this 
approach, two biocatalysts were effectively combined in a 
cascade reactor. 
The biocatalyzed resolution of flurbiprofen 33 has been carried 
out in a flow system, using the commercially available immobilized 
lipase, Novozyme 435 or mycelium-containing whole cells, in both 
batch and flow reactors (Scheme 21).[72] When using either 
immobilized lipase, or mycelia, an in-line purification step was 
added; a basic resin was used to separate the unreacted acid 
from the ester product in the continuous flow system. When using 
the commercially available catalyst the excess water was 
absorbed by including molecular sieves. Use of the cell mycelia 
facilitates separation from the reaction mixture without the need 
for immobilization, in addition to this they also remove the excess 
water.[72d;73] When using both the commercially available catalyst, 
and the whole cell systems, the product was obtained in excellent 
enantiopurity and high conversion; the use of flow reactors 
reduced the reaction time in both cases. 
 
Scheme 21. Biocatalyzed continuous synthesis of flurbiprofen 33  
Continuous flow has been utilized in the synthesis of 
cyanoacetates using two distinct biocatalysts, CAL-B and a 
hydroxynitrile lyase (HNL) in a linked multistep flow process 
(Scheme 22).[74] The CAL-B hydrolyses 34 to release HCN, which 
is then utilized by the lyase in the synthesis of cyanohydrins, 
which are chemically acylated before isolation. The advantage of 
this continuous flow system is that it avoids the need to use 
hydrogen cyanide gas. The use of a surrogate which is reacted in 
situ, means that there should only ever be a very small amount of 
the HCN in the system. The use of a flow-system also allowed an 
additional protecting group to be easily added to improve the 
overall stability of the target cyanohydrins. This could potentially 






be effected using a biocatalyzed transesterification step to add 
the protecting group, rather than the chemical step; lipases have 
previously been used to resolve cyanohydrins via both hydrolysis 
and transesterification.[75]  
 
Scheme 22. In situ generation of HCN gas for asymmetric synthesis of 
cyanohydrins 
It is evident that the use of biocatalysis in organic synthesis is 
greatly facilitated through immobilization and continuous flow and 
enhanced activity in this area is anticipated. Advances in support 
materials enable the use of higher flow rates and a wider range of 
solvents to enable telescoping of biocatalyzed reaction steps as 
part of an overall synthetic process.  
 
2. Dynamic kinetic resolution and combining 
chemo- and biocatalysts 
The use of multiple biocatalysts or a combination of chemo- and 
biocatalysts in the same reaction vessel is an attractive method of 
synthesis, since it can reduce the reaction time and product 
purification required. Dynamic kinetic resolution is an attractive 
method of increasing the yield of kinetic resolution reactions 
(Scheme 23). While biocatalysis has enormous potential for 
dynamic kinetic resolution, in practice, ensuring the biocatalyst is 
compatible with the conditions employed for racemization can be 
limiting.[2b;2c;76] [77] However, with the availability of a wide range of 
immobilization techniques, biocatalysts can be stabilized so they 
can tolerate harsher reaction conditions and indeed can 
potentially be protected from these conditions through 
compartmentalization especially in flow systems. 
The dynamic kinetic resolution of alcohols using metal-based 
racemization catalysts in combination with lipases is well reported 
and there have been several reviews on the use of complexes of 
metals such as iron, ruthenium, and iridium.[77b-e;78] Acids and 
bases, zeolite, even light activated catalysts have also been used 
as racemization catalysts for the dynamic kinetic resolution of 
alcohols.[79]  
 
Scheme 23. Dynamic kinetic resolution, using alcohols as an example 
The lipase-catalyzed resolution of the hemiacetal moiety of 
sugars is widely reported and utilizes the dynamic ring 
opening/closing of the hemiacetal in place of the addition of an 
external catalyst.[80] The same ring-opening and ring-closing was 
utilized within our group for the dynamic kinetic resolution of 
2-chromanol 35 (Scheme 24).[81] The use of such systems takes 
advantage of the instability of the ring structure, or the reversibility 
of reaction that occurs naturally, without the need for an external 
catalyst. Another example of this is the use of prochiral ketones 
(Scheme 25). The enol can be trapped by chemical acylation, 
taking advantage of the keto-enol tautomerization, and the 
resulting enol acetate can be selectively hydrolyzed using a 
hydrolytic enzyme.[82] Spontaneous racemization has also been 
applied to the synthesis of 1,2-diaminopentane derivatives and 
3,4-dihydroisocoumarins (Figure 5).[83] The use of prochiral 
substrates (desymmetrization) is an attractive alternative to 
kinetic resolution; some examples of such compounds which 
have been used as intermediates in the synthesis of 
pharmaceutical compounds are shown in Scheme 26.[84]  
 
Scheme 24. Spontaneous racemization 
 
Scheme 25. Dynamic kinetic resolution with no external catalysts: using 
equilibria for racemization  
 
Figure 5. 1,2-Diaminopentane derivatives, and 3,4-dihydroisocoumarin 
derivatives 
 
Scheme 26. Lipase-mediated resolution of prochiral compounds  
The dynamic kinetic resolution of α-hydroxy ketones, such as 
benzoin 36, via a diketone intermediate 37 has been reported 
(Scheme 27).[85] This dynamic kinetic resolution has been carried 
out in both batch and continuous mode by variation of support 
used for lipases in combination with various chemocatalysts, as 






well as examination of solvent effect, to make the reaction 
greener.[86] The use of a readily available ruthenium catalyst in 
combination with a base was initially considered at 50 °C. 
However, it was shown that the right combination of catalyst and 
ligand allowed the reaction to be carried out at a lower 
temperature (room temperature). 
 
Scheme 27. Dynamic kinetic resolution of benzoin 26 
Akai et al. reported the lipase/metal-catalyzed dynamic kinetic 
resolution of racemic allylic alcohols (Scheme 28).[87] The acyl 
group installed in the lipase-catalyzed transesterification was 
carefully chosen so that it would undergo further reaction, making 
the reaction more atom economical, as the acyl group did not 
require removal after the resolution step.[88] The oxovanadium 
catalyst carried out a racemization/isomerization of the allylic 
alcohol starting material. As an illustrative example, this 
methodology was applied to the total synthesis of (−)-himbacine 
(−)-38, furnishing the product with excellent enantioselectivity.[89] 
 
 
Scheme 28. Combining lipase-catalyzed resolution and an intramolecular 
Diels-Alder reaction 
The combination of a biocatalyzed reduction and a chemical 
oxidation was also reported. The bioreduction was carried out first, 
followed by sulfur oxidation using a chiral chemocatalyst (Scheme 
29).[90] Potentially, the bioreduction could be combined with a 
biocatalytic sulfur oxidation step in place of the chemocatalyzed 
step. Biocatalyzed sulfur oxidation can avoid the over oxidation to 
the sulfone which can be a problem for chemical catalysis.[91] The 
synthesis of sulfur containing ketones and subsequent 
bioreduction to give the corresponding alcohols has also been 
reported, in a one-pot photobiocatalytic cascade (Scheme 30).[92] 
The initial Michael reaction is light activated, forming a sulfide 
from a thiol and an α,β-unsaturated ketone. Varying the choice of 
ketoreductase gave access to both enantiomers of the 
1,3-mercaptoalcohol products. 
 
Scheme 29. Combining a bioreduction and a chemical oxidation 
 
Scheme 30. One-pot photobiocatalytic cascade 
These selected examples highlight the potential of combining 
biotransformations and other reactions as a powerful synthetic 
strategy. Kinetic resolution is useful in the synthesis of 
enantiopure compounds, but an inherent disadvantage of this 
technique is the limited yield. The combination of biocatalysts with 
racemization catalysts to give a dynamic kinetic resolution is a 
very useful technique, but the conditions under which the two 
catalysts work can be very different. The use of immobilized 
catalysts which are, by-design, more stable under the desired 
conditions can facilitate the combination of biocatalysts and 
organo- or metal-catalysts. The physical separation of the 
catalysts, in a continuous flow system can also enable the 
combination of “incompatible” catalysts. 
3. Examples of enzymes in pharmaceutical & 
natural product synthesis 
There have been several reviews in the past 10 years of the 
applications of biocatalysts in the synthesis of drug products and 
intermediates.[93] The focus of this section is recent examples of 
synthetic routes which utilize biocatalytic steps specifically in 
relation to the use of enabling technology. 
Biocatalytic retrosynthesis is a relatively new concept, pioneered 
by Turner et al., which recognizes the need for the integration of 
biocatalysis in retrosynthetic analysis, choosing disconnections 
with consideration for reactions which can be catalyzed by 
enzymes.[94] There have been a number of reported total 
syntheses using biocatalysis either as a single resolution step, or 
a multistep sequence. More importantly, the use of biocatalysts in 
the drug discovery stage has significant potential. For example, 
recently the use of a laccase-mediated enantioselective oxidation 
was reported in the synthesis of a series of dihydrobenzofurans 
for in vitro testing 
(
Scheme 31).[95] Biocatalysis is particularly suited to this use as the 
essentially by-product free reactions means that subsequent 






purification is not necessary; a biological oxidant means that the 
use of costly metal and/or chiral oxidants can be avoided.[96] 
Scheme 31. Biocatalyzed medicinal chemistry route to highly substituted 
dihydrobenzofurans 
Lipases have been used for the resolution of propanoic acid 
derived non-steroidal anti-inflammatory drugs through both the 
resolution of the 2-arylalkylalcohol precursors and the direct 
resolution of the α-alkyl carboxylic acids (Scheme 32).[97] 
Structurally related compounds, 2-phenylalkanols and 
3-arylalkanoic acids (also called β-aryl alkanoic acids) have 
previously been resolved using hydrolases by our group, initially 
focusing on commercially available hydrolases but more recently, 
demonstrating the power of exploiting a metagenomic approach 
to identify a novel hydrolase with a complimentary substrates 
scope.[98] Their resolution and use for the synthesis of natural 
products (R)- and (S)-curcumene 39 and curcuphenol 40 has also 
been reported (Scheme 32).[99] A related compound, alkenoic acid 
41 has been resolved and used in the chemoenzymatic synthesis 
of femoxetine 42 (Scheme 33), with one of the two stereocentres 
installed by lipase-catalyzed resolution.[100] A tandem metal-lipase 
dynamic kinetic resolution was also developed for the resolution 
of alkenoic acid 40 to further increase the yield of the 
resolution.[101]  
Scheme 32. Use of arylalkanols and arylalkanoic acids in synthesis 
Scheme 33. Synthesis of femoxetine 42 
Recently, the total synthesis of δ-lactones (+)- and (−)-cis-
osmundalactone 43 by a three step chemoenzymatic cascade 
from a readily available starting material has been described 
(Scheme 34).[102] By selecting an (S)- or (R)- selective alcohol 
dehydrogenase, both enantiomers of the furfuryl alcohol 44 can 
be accessed, which are then subjected to a biocatalyzed-aerobic 
ring expansion using a chloroperoxidase, which can be carried 
out as a one-pot transformation. The lactone intermediates are 
then diastereoselectively reduced using a transition metal catalyst.  
A “one-pot-like” synthesis of vitamin B6 intermediate 
(R)-pantolactone (R)-45 was reported, combining an 
organocatalyzed aldol reaction and a biocatalyzed reduction, with 
in situ removal of the volatile by-products before the biocatalyzed 
step and continuous removal of the acetone 32 by-product from 
the biocatalyzed reaction (Scheme 35).[104]103] In contrast to the 
other reactions discussed in this section, the stereochemistry is 
provided by the organocatalyst, and further enhanced by the 
biocatalyst.  
Scheme 34. One-pot chemoenzymatic cascade for the synthesis of 
osmundalactone 43 
Scheme 35. Synthesis of (R)-45 by combined chemo- and biocatalysis 
Akai et al. reported a one-pot domino biocatalytic 
transesterification/1,3-dipolar cycloaddition. The biocatalytic 
resolution is the key diastereoselective step in the synthesis of 
(−)-rosmarinecine 46 (Scheme 36).[105] It is also the first example 
of both a domino transesterification/1,3-dipolar cycloaddition and 
a total synthesis of (−)-46 which does not use chiral pool starting 
materials or chiral auxiliaries.  
 
Scheme 36. Synthesis of (−)-rosmarinecine 46 via a tandem 
transesterification/ dipolar cycloaddition 
In an excellent example of the flexible use of multiple biocatalysts, 
Berglund et al. reported a total synthesis of capsaicin analogues 
from a primary alcohol 47 using a metal-catalyzed oxidation to 
produce aldehyde 48, followed by a one-pot amine 
transaminase-catalyzed reductive amination and a lipase-
catalyzed amidation, using a fatty acid as the acyl donor (Scheme 
37).[106] The authors initially investigated the use of a biocatalyzed 






oxidation, which could be coupled with the amine transaminase; 
the alcohol dehydrogenase could function as a redox partner for 
the regeneration of cofactors for the L-alanine dehydrogenase 
(L-AlaDH) as well as the oxidation of the alcohol 47. However, this 
step was less efficient than the palladium catalyzed oxidation, 
giving 61% conversion as opposed to 87% conversion. In the 
development of this route, both the chemocatalyzed steps and the 
biotransformations were considered, and the two methods were 
combined in different ways. This is an excellent example of the 
combination of biocatalysts and chemocatalysts in the synthesis 
of a natural product and its analogues. Another step considered 
was the retroaldol reaction of 49 to produce aldehyde 48 in situ, 
catalyzed by the L-alanine which is already present in the reaction 
mixture as it is used as a cofactor for the amine transaminase 
reaction.  
 
Scheme 37. Combined chemo- and biocatalyzed routes to capsaicin 
analogues 
Renata et al. report the use of an overexpressed lysine 
hydroxylase as a clarified cell lysate, eliminating the need for 
costly protein purification.[107] The use of co-expressed chaperone 
proteins increased the expression and stability of the protein of 
interest. The lysine hydroxylase was used to make multigram 
quantities of the chiral material 49 which was further reacted to 
give natural product tambromycin 50 via the protected tambroline 
51 (Scheme 38). By modifying the host cell, extra stability was 
imparted on the system. 
 
Scheme 38. Synthesis of natural product tambromycin 50 
The chemoenzymatic synthesis of (S)-rivastigmine 52 was 
reported, using a lipase to impart the stereochemistry, through 
CAL-B-mediated transesterification of intermediate 53 (Scheme 
39).[108] The reuse of the CAL-B in this process was also explored, 
where the enzyme was shown to retain activity through 6 reaction 
cycles. The racemization of the alcohol 53 was carried out using 
a ruthenium catalyst for a dynamic kinetic resolution, further 
enhancing the value of this synthesis.[109] The use of baker’s 
yeast-derived alcohol dehydrogenase for the stereoselective 
reduction of the ketone 54, has also been reported, where the 
biocatalyst was identified by screening a large range of 
commercially available biocatalysts.[110] A novel transaminase has 
also been used for the reductive amination of 54 and this is a more 
direct route to (S)-52 than the alcohol dehydrogenase.[111] 
 
Scheme 39. Synthesis of (S)-rivastigmine 52 
Saxagliptin 55 was developed by Bristol-Meyers Squibb as a 
treatment for diabetes.[112] A key intermediate in the synthesis of 
55 is the N-protected glycine derivative 56, which was prepared 
by reductive amination of the keto acid 57 using a mutated 
phenylalanine dehydrogenase, a NAD dependent transferase 
(Scheme 40).[113] The process was coupled with formate 
dehydrogenase for cofactor recycling. A whole cell catalyst, which 
co-expresses multiple enzymes can be useful for processes 
which require NAD dependent enzymes; the redox coupling 
partners can be produced in the same cell system, negating the 
need for an external enzyme to be added. (S)-tert-Leucine (S)-58, 
an intermediate in the synthesis of atazanavine, boceprevir and 
telaprevir, has been synthesized in a whole cell system producing 
both the required leucine dehydrogenase, which carries out the 
reductive amination on the keto acid 59, and the formate 
dehydrogenase, for cofactor recycling (Scheme 41).[114] 
 
Scheme 40. Synthesis of Saxagliptin 55 







Scheme 41. Synthesis of (S)-tert-leucine 58 
The integration of biocatalysed steps in pharmaceutical synthesis 
is more challenging with more structurally complex targets. With 
added structurally complexity, the compatibility with wild-type 
enzymes is less likely. However, the advent of directed evolution 
can greatly with the resolution of these compounds. The key 
enantioselective step in the synthesis of montelukast 60 
(Singulair®, Merck & Co.) has been achieved using an 
engineered ketoreductase in place of (–)-DIP-Cl and was run on 
a >200 kg scale (Scheme 42).[115] Another drug developed by 
Merck & Co., suvorexant 61, requires only a short synthesis 
involving a tandem transamination and ring annulation using an 
evolved transaminase (Scheme 43) replacing the classical 
resolution in the previous synthetic route.[116] Introducing the 
stereocentre at a more advanced stage means that the synthesis 
can be carried out racemically, and that the racemization of the 
stereocentre can be limited. 
 
Scheme 42. Synthesis of montelukast sodium 60 
 
Scheme 43. Synthesis of suvorexant 61 
For atorvastatin 62 (Lipitor®) there are several intermediates 
which can be produced in enantiomerically pure forms using 
biocatalyzed reactions and this area has been reviewed.[117] Since 
this review, a two-step three enzyme process has been reported 
using a ketoreductase (KRED) and glucose dehydrogenase 
(GDH) in a redox coupling step, and a halohydrin dehydrogenase 
(HHDH) to carry out a functional group conversion via an 
intermediate epoxide 63 (Scheme 44).[118] The use of reductase 
to resolve the intermediate 64 can suffer from product inhibition, 
i.e. the product can slow down the reaction. Wang et al. reported 
the use of a dual-purpose functionalized resin for the 
immobilization of the enzyme. The support material also adsorbs 
the product, which prevents product inhibition, allowing increased 
substrate loading.[119] Recently, the biocatalyzed synthesis of 
intermediate ester 65 has been reported using a carbonyl 
reductase, identified through directed evolution.[120] 
 
Scheme 44. Chemoenzymatic synthesis of intermediates of atorvastatin 62 
The diester intermediate 66 in the synthesis of pregabalin 67 was 
resolved using a commercially available lipase.[121] A recycling 
step was also developed, where the unreacted ester 66 from the 
resolution could be recycled to enhance the efficiency of the 
reaction (Scheme 45, B). The route is particularly well set up for 
the potential transfer to continuous flow, for the 
resolution/recycling. Another route to 67 utilized nitrilases for an 
initial desymmetrization step, followed by a Curtius 
rearrangement and hydrolysis (Scheme 45, A).[122] This route 
allowed access to both pregabalin 67 and baclofen 68. The use 
of a mutated lipase from Thermomyces lanuginosus has also 
been reported in the resolution of 66, giving increased activity 
against 69.[123] Recently, the use of transaminases has been 
applied to the resolution of pregabalin 67 and brivaracetam 70 
intermediate α-chiral aldehydes (Scheme 45 C).[124] The 
aldehydes racemize under the biotransformation conditions, 
specifically in the presence of the amine donor isopropylamine 31, 
furnishing an effective DKR by taking advantage of the inherent 
equilibrium under the reaction conditions. 
Several biocatalytic routes have been developed to access 
rasagiline mesylate (R)-71, a commercially marketed treatment 
for Parkinson’s disease (Scheme 46). The resolution of 
(S)-1-indanol 72, followed by a stereoinversion using Mitsunobu 
chemistry and a Staudinger reduction gives the enantiopure 
amine 73.[125] The resolution of the amine has also been 
developed, combining the CAL-B-catalyzed transesterification of 
amine 73 with an in situ racemization step.[126] A route to 
rasagiline 71 has also been reported using imine reductases 
(IREDs) to convert the ketone 74 directly to the target compound 
(R)-71.[127] The enantiomer (S)-71, can also be accessed through 
the use of an (S)-selective imine reductase. While the IRED route 
seems the most logical route to use, factors such as scalability 
and knowledge of the chemistry involved would need to be 
carefully considered; CAL-B is a very well-studied lipase, and has 
been used in industrial processes previously, thus, may be more 
readily employed than the lesser known biocatalyst. Screening of 






a library of mutant biocatalysts (IRED) gave excellent results here. 
Equally, the use of a well-characterized biocatalyst in conjunction 
with a racemization step also gives the product with excellent 
enantiopurity. 
 
Scheme 45. Resolution of pregabalin precursors and synthesis of related 
compounds 68 & 70 
Enzymatic reactions have been used in the enantioselective 
synthesis of two enantiopure advanced intermediates of 
γ-secretase inhibitor 75, on a multikilogram scale (Scheme 
47).[128] The transaminase was used in conjunction with 
isopropylamine to effect enantioselective reductive amination of 
tetralone 76; while an additional cofactor recycling step was 
required for the alcohol dehydrogenase-mediated reaction to 
produce the enantiopure ester 77. 
A chemoenzymatic route to norsertraline 78, an API structurally 
related to the Pfizer antidepressant sertraline, has been reported 
through the resolution of 1-aminotetralin 79 by transesterification, 
and retention of the acyl group throughout the synthesis as a 
protecting group (Scheme 48).[129] The use of CAL-B at elevated 
temperatures in conjunction with a racemization catalyst is the 
first step in a six- step synthesis from commercially available 79. 
 
 
Scheme 46. Enzymatic routes to rasagiline mesylate 71 
 
Scheme 47. Synthesis of γ-secretase inhibitor 75  
 
Scheme 48. Dynamic kinetic resolution of 1-aminotetralin 79 
4. Conclusions 
Biocatalytic transformations offer a very powerful approach for 
enantioselective synthesis, frequently occurring under mild 
conditions and with extraordinary selectivity obviating the need for 
complex protecting group strategies due to functional group 
tolerance. Nevertheless, there are practical challenges 
associated with the use of biocatalysis such as limited substrate 
scope, stability and reusability. Recent technological advances 
enable the enhanced use of biocatalytic approaches for 
enantioselective synthesis: including molecular biology 
techniques leading to modified or novel biocatalysts with 
improved properties, enzymes stabilization through 
immobilization, and the potential to use biocatalysts as part of a 
reaction cascade, either in traditional batch reactors or in 
continuous flow.  
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